Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine

NCT04435652 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04435652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04435652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 1, 2020
Completion date
November 30, 2022
Enrollment
492 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric or gastroesophageal junction adenocarcinoma